The number of patients undergoing intravitreal injections is growing exponentially. Long term treatments with anti-VEGF agents and/or steroids are now common in a number of retinal diseases. However, the significance of such treatment strategies on the pathogenesis of glaucoma or even how they may affect glaucoma management is not entirely clear. The possible impact of angiogenic and inflammation modulators in neuron cell survival and activity will be made. From a clinical point of view, it will be discussed if, how and which of these agents are more likely to affect intraocular pressure management.